SCNI Key Statistics, Chart & Performance
The current stock price of SCNI is 0.9359 USD. In the past month the price decreased by -35.46%. In the past year, price decreased by -72.79%.
SCNI Latest News, Press Relases and Analysis
SCNI Competitors/Peers
Symbol | Company Name | TA | FA | PE | Market Cap |
|---|---|---|---|---|---|
| ABBV | ABBVIE INC | 24.09 | 402.18B | ||
| AMGN | AMGEN INC | 15.76 | 185.50B | ||
| GILD | GILEAD SCIENCES INC | 15.57 | 158.22B | ||
| VRTX | VERTEX PHARMACEUTICALS INC | 24.89 | 110.80B | ||
| REGN | REGENERON PHARMACEUTICALS | 17.43 | 83.16B | ||
| ALNY | ALNYLAM PHARMACEUTICALS INC | 872.78 | 58.35B | ||
| INSM | INSMED INC | N/A | 43.23B | ||
| NTRA | NATERA INC | N/A | 32.54B | ||
| BIIB | BIOGEN INC | 10.87 | 26.67B | ||
| UTHR | UNITED THERAPEUTICS CORP | 18.51 | 22.09B | ||
| INCY | INCYTE CORP | 16.46 | 20.63B | ||
| EXAS | EXACT SCIENCES CORP | N/A | 19.21B |
Related stock screener links
About SCNI
Company Profile
Scinai Immunotherapeutics Ltd. is a clinical stage biopharmaceutical company, which engages in the development and commercialization of immunomodulation therapies for infectious diseases. The Company’s core focus is to develop NanoAbs for the treatment of various diseases such as COVID-19, psoriasis, and asthma. The firm's product NanoAb is based on alpaca-derived nanosized antibodies (NanoAbs), also known as VHH-antibodies. Additionally, the Company offers manufacturing facilities, aseptic fill and finish suites, laboratories, and experienced professionals for other research and development companies. Scinai Immunotherapeutics Ltd operates in Israel.
Company Info
SCINAI IMMUNOTHERAPEUTICS LT
Jerusalem Biopark, 2Nd Floor, Hadassah Ein Kerem Campus
JERUSALEM IL
Employees: 31
Phone: 97289302529
SCINAI IMMUNOTHERAPEUTICS LT / SCNI FAQ
What does SCNI do?
Scinai Immunotherapeutics Ltd. is a clinical stage biopharmaceutical company, which engages in the development and commercialization of immunomodulation therapies for infectious diseases. The Company’s core focus is to develop NanoAbs for the treatment of various diseases such as COVID-19, psoriasis, and asthma. The firm's product NanoAb is based on alpaca-derived nanosized antibodies (NanoAbs), also known as VHH-antibodies. Additionally, the Company offers manufacturing facilities, aseptic fill and finish suites, laboratories, and experienced professionals for other research and development companies. Scinai Immunotherapeutics Ltd operates in Israel.
What is the current price of SCNI stock?
The current stock price of SCNI is 0.9359 USD. The price increased by 1.34% in the last trading session.
What is the dividend status of SCINAI IMMUNOTHERAPEUTICS LT?
SCNI does not pay a dividend.
What is the ChartMill technical and fundamental rating of SCNI stock?
SCNI has a ChartMill Technical rating of 0 out of 10 and a ChartMill Fundamental rating of 1 out of 10.
Is SCINAI IMMUNOTHERAPEUTICS LT (SCNI) stock a good buy?
This depends on your investment goals. Check the Technical and Fundamental Analysis tabs for insights on SCNI.
What is the market capitalization of SCNI stock?
SCINAI IMMUNOTHERAPEUTICS LT (SCNI) has a market capitalization of 2.95M USD. This makes SCNI a Nano Cap stock.
Can you provide the ownership details for SCNI stock?
You can find the ownership structure of SCINAI IMMUNOTHERAPEUTICS LT (SCNI) on the Ownership tab.
SCNI Technical Analysis
SCNI Fundamental Analysis
ChartMill assigns a fundamental rating of 1 / 10 to SCNI. SCNI may be in some trouble as it scores bad on both profitability and health.
SCNI Financial Highlights
Over the last trailing twelve months SCNI reported a non-GAAP Earnings per Share(EPS) of 3.03.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PM (TTM) | 728.88% | ||
| ROA | 40.51% | ||
| ROE | 61.03% | ||
| Debt/Equity | 0.04 |